Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8485851 | 0.86 | KMT2A (0.46) | LMNASMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL3377395 | 0.78 | LMNA (0.50) | LMNASMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL31090029 | 0.72 | LMNA (0.49) | LMNASMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL6395648 | 0.69 | POLB (0.36) | LMNAKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL6393893 | 0.67 | HCAR2 (0.45) | KMT2AMEN1MAPTALDH1A1CYP3A4 | |
| SCHEMBL4560425 | 0.66 | TYMP (0.56) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL1445690 | 0.66 | TYMP (0.56) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL8761974 | 0.65 | MAPK1 (0.47) | KMT2AMEN1ALDH1A1CYP2C9CYP3A4 | |
| SCHEMBL5154556 | 0.64 | NPC1 (0.55) | LMNASMN1; SMN2ALDH1A1NPC1CYP3A4 | |
| Sulfuric Acid SCHEMBL28174767 | 0.64 | CA5A (0.46) | LMNAALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | claimed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | claimed |
| EP-2007729-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-31 | — | — | EP | claimed |
| EP-1911747-A1 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | claimed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | claimed |
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | disclosed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | disclosed |
| EP-2007729-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-31 | — | — | EP | disclosed |
| EP-1911747-A1 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | disclosed |
| US-6835726-B2 | Pyrimidine derivatives | AMGEN INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040006068-A1 | Pyrimidine derivatives | TULARIK INC. | 2004-01-08 | — | — | US | disclosed |
| EP-1056742-B1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| US-6528513-B2 | Viricides; especially cytomegalo virus | TULARIK INC | 2003-03-04 | — | — | US | disclosed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20010018436-A1 | Pyrimidine derivatives | TULARIK INC. | 2001-08-30 | — | — | US | disclosed |
| US-6200977-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1056742-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999041253-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | LMNA 4154/4885SMN1; SMN2 2956/4885KMT2A 2560/4885 |
| US-20010018436-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | LMNA 4485/4885SMN1; SMN2 2908/4885KMT2A 3049/4885 |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | LMNA 2234/4885SMN1; SMN2 4285/4885KMT2A 2232/4885 |
| US-20040006068-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | LMNA 4485/4885SMN1; SMN2 2908/4885KMT2A 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.